Replies to post #323358 on Amarin Corp Plc (AMRN)

[sts66]

Doesn't mean an EU country will pay for off-label use:

https://joppp.biomedcentral.com/articles/10.1186/s40545-020-00249-9

Lack of reimbursement for off-label drugs for new treatment indications vary from country to country in Europe. Often, off-label use of drugs is not reimbursed. However in daily clinical practice, especially for cancer and HIV drugs, in contrast to auto-immune diseases, reimbursement of these off-label drugs is possible due to strong media and political support.

Just like some people on this board being refused insurance coverage for V because the PA requirements are too onerous.